Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Research Design | 2 | 2020 | 729 | 1.020 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2019 | 28 | 0.680 |
Why?
|
| Steroids | 1 | 2019 | 84 | 0.650 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.510 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2023 | 2 | 0.220 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 33 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2021 | 62 | 0.190 |
Why?
|
| Glycomics | 1 | 2021 | 29 | 0.180 |
Why?
|
| Pituitary Neoplasms | 1 | 2021 | 52 | 0.180 |
Why?
|
| Intraoperative Care | 1 | 2021 | 91 | 0.180 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2020 | 13 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 468 | 0.180 |
Why?
|
| Sample Size | 1 | 2020 | 79 | 0.180 |
Why?
|
| Adenoma | 1 | 2021 | 132 | 0.170 |
Why?
|
| Rare Diseases | 1 | 2019 | 41 | 0.170 |
Why?
|
| Quinazolines | 1 | 2019 | 70 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 41 | 0.170 |
Why?
|
| Glycoproteins | 1 | 2021 | 238 | 0.170 |
Why?
|
| Body Image | 1 | 2020 | 100 | 0.170 |
Why?
|
| Aortic Valve | 1 | 2021 | 249 | 0.160 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 177 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2021 | 453 | 0.160 |
Why?
|
| Drosophila Proteins | 1 | 2019 | 44 | 0.160 |
Why?
|
| Immunoglobulins | 1 | 2019 | 97 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2019 | 190 | 0.160 |
Why?
|
| Random Allocation | 1 | 2019 | 442 | 0.160 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 80 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 206 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2020 | 146 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 230 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2019 | 248 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2019 | 307 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 411 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.140 |
Why?
|
| Synapses | 1 | 2019 | 222 | 0.140 |
Why?
|
| Proprotein Convertases | 1 | 2016 | 8 | 0.140 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2016 | 21 | 0.140 |
Why?
|
| Dendrites | 1 | 2016 | 44 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2019 | 706 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 931 | 0.130 |
Why?
|
| HIV Infections | 1 | 2023 | 791 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 561 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1851 | 0.120 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2016 | 617 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 1536 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1293 | 0.090 |
Why?
|
| Prognosis | 2 | 2023 | 2093 | 0.070 |
Why?
|
| Humans | 7 | 2023 | 68618 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2023 | 7277 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 33 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 64 | 0.050 |
Why?
|
| Mastectomy | 1 | 2021 | 57 | 0.050 |
Why?
|
| Operative Time | 1 | 2021 | 45 | 0.050 |
Why?
|
| Molecular Imaging | 1 | 2021 | 45 | 0.050 |
Why?
|
| Glycosylation | 1 | 2021 | 185 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 446 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 467 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 132 | 0.040 |
Why?
|
| Thiophenes | 1 | 2019 | 76 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 260 | 0.040 |
Why?
|
| Structural Homology, Protein | 1 | 2019 | 16 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2019 | 67 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 176 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 304 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2019 | 128 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2019 | 190 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 71 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2021 | 306 | 0.040 |
Why?
|
| Female | 4 | 2021 | 38074 | 0.040 |
Why?
|
| Phylogeny | 1 | 2019 | 197 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 1046 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 493 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 780 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 332 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 786 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 1083 | 0.040 |
Why?
|
| Animals | 3 | 2019 | 20881 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 447 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2016 | 38 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 61 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1342 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1027 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 468 | 0.030 |
Why?
|
| Morphogenesis | 1 | 2016 | 159 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 1851 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1615 | 0.030 |
Why?
|
| Middle Aged | 2 | 2021 | 21147 | 0.030 |
Why?
|
| Child | 1 | 2021 | 6405 | 0.020 |
Why?
|
| Male | 2 | 2021 | 37321 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 8474 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 8912 | 0.020 |
Why?
|
| Adult | 1 | 2020 | 21403 | 0.010 |
Why?
|